MYH11: A Protein Targeted for Cancer and Neurodegenerative Diseases

Target Name: MYH11

NCBI ID: G4629

MYH11

MYH11: A Protein Targeted for Cancer and Neurodegenerative Diseases

Myosin heavy chain 11 (MYH11) is a protein that plays a critical role in muscle function and growth. It is a transmembrane protein that contains a unique domain structure that is characterized by a conserved N-terminal alpha-helix, a variable N-terminal region, and a C-terminal region that is rich in acidic amino acids. Despite its importance for muscle development and function, MYH11 is not well understood, and there are limited research studies available on its role in human disease.

Despite its limited function, MYH11 has been identified as a potential drug target in several diseases. Its unique domain structure and location on the membrane make it an attractive target for small molecules, antibodies, or other therapeutic agents. MYH11 has also been shown to be Involved in several diseases, including cancer, neurodegenerative diseases, and autoimmune diseases.

MYH11 and Cancer

One of the most promising applications of MYH11 as a drug target is its potential to inhibit cancer cell growth and metastasis. MYH11 has been shown to be involved in several cellular processes that are critical for cancer cell growth, including cell division, cell migration, and angiogenesis. Several studies have shown that inhibiting MYH11 can inhibit the growth and metastasis of several types of cancer, including breast, ovarian, and colorectal cancer.

MYH11 and Neurodegenerative Diseases

Neurodegenerative diseases are a group of conditions that are characterized by progressive loss of nervous system cells and their associated symptoms. These conditions include Alzheimer's disease, Parkinson's disease, and Huntington's disease. MYH11 has been shown to be involved in several neurodegenerative diseases, including the regulation of neurotransmitter release and the modulation of pain perception.

MYH11 and Autoimmune Diseases

Autoimmune diseases are a group of conditions that are characterized by the immune system attacking the body's own tissues. These conditions include rheumatoid arthritis, lupus, and multiple sclerosis. MYH11 has been shown to be involved in several autoimmune diseases, including the regulation of immune cell function and the modulation of inflammation.

MYH11 as a Biomarker

MYH11 has also been identified as a potential biomarker for several diseases. Its unique domain structure and location on the membrane make it an attractive target for diagnostic agents, such as antibodies or nucleic acid-based probes. Several studies have shown that the levels of MYH11 have been altered in several diseases, including cancer, neurodegenerative diseases, and autoimmune diseases.

MYH11 as a Therapeutic Agent

Several studies have shown that inhibiting MYH11 can be effective in treating several diseases, including cancer, neurodegenerative diseases, and autoimmune diseases. MYH11 has been shown to interact with several molecules, including tyrosine kinase, heat shock protein, and transcription factors. These interactions make it an attractive target for small molecules, antibodies, or other therapeutic agents.

Conclusion

MYH11 is a protein that plays a critical role in muscle function and growth. Despite its importance, there is limited understanding of its role in human disease. Its unique domain structure and location on the membrane make it an attractive target for small molecules, antibodies, or other therapeutic agents. Several studies have shown that inhibiting MYH11 can inhibit the growth and metastasis of cancer cells, and its levels have been altered in several neurodegenerative diseases and autoimmune diseases. Further research is needed to fully understand the role of MYH11 in human disease and to develop effective treatments.

Protein Name: Myosin Heavy Chain 11

Functions: Muscle contraction

The "MYH11 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MYH11 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets